Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07313813) titled 'A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Type 2 Diabetes Mellitus (T2DM)
Intervention:
Drug: Dulaglutide
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 2025
Target Sample Size: 20
Countries of Recruitment:
Singapore
...